Recursion Pharmaceuticals is currently positioned below all key moving averages, indicating bearish momentum. The stock is trading 18.2% below its 20-day SMA, 22.5% below its 50-day SMA and ...
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results